文献速递肿瘤 PET/CT

Al18F-NOTA-FAPI用于成纤维细胞活化蛋白靶向肿瘤显像的临床转化评价

Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-06-24

本研究开发了铝-[18F]氟化物(Al18F)标记的NOTA偶联成纤维细胞活化蛋白抑制剂(FAPI)探针Al18F-NOTA-FAPI,用于FAP靶向肿瘤显像。在临床前细胞与小鼠模型验证后,对首批10例癌症患者进行PET/CT显像,结果显示该探针放化产率33.8±3.2%(手动合成,n=10),放化纯度>99%,比活度9.3-55.5 MBq/nmol,全身有效剂量1.24E-02 mSv/MBq,低于几种其他FAPI探针,且多数器官SUVmean低于2-[18F]FDG,能检出更多病灶。

要点

  • Al18F-NOTA-FAPI手动合成放化产率33.8±3.2%,放化纯度>99%。
  • 全身有效剂量1.24E-02 mSv/MBq,低于68Ga-FAPI-04、-46和-74。
  • 患者多数器官SUVmean低于2-[18F]FDG,肝、脑、骨髓尤为明显。

核心结论

  • Al18F-NOTA-FAPI探针成功制备并应用于FAP靶向肿瘤PET/CT显像,在U87MG荷瘤小鼠和癌症患者中显示良好显像质量与肿瘤检出效能。

研究设计与样本

  • 临床转化研究:优化Al18F-NOTA-FAPI放射标记,用U87MG和A549细胞系完成摄取与竞争结合实验,在健康昆明小鼠和/或U87MG模型小鼠研究生物分布、药代动力学、辐射剂量学及肿瘤显像效能,经伦理批准后对首批10例癌症患者行PET/CT显像。

主要发现

  • 手动合成Al18F-NOTA-FAPI放化产率33.8±3.2%(n=10),放化纯度>99%,比活度9.3-55.5 MBq/nmol。
  • Al18F-NOTA-FAPI全身有效剂量估计为1.24E-02 mSv/MBq,低于68Ga-FAPI-04、68Ga-FAPI-46和68Ga-FAPI-74等几种其他FAPI探针。
  • U87MG荷瘤小鼠micro PET/CT显像和生物分布研究显示Al18F-NOTA-FAPI具有良好的肿瘤检出效能。
  • 患者器官生物分布研究中,Al18F-NOTA-FAPI在多数器官SUVmean低于2-[18F]FDG,尤其肝脏(1.1±0.2 vs. 2.0±0.9)、脑(0.1±0.0 vs. 5.9±1.3)和骨髓(0.9±0.1 vs. 1.7±0.4)。
  • Al18F-NOTA-FAPI未显示广泛骨摄取,在数例患者PET/CT显像中检出的病灶数多于2-[18F]FDG。

临床怎么用

  • Al18F-NOTA-FAPI可用于FAP靶向肿瘤PET/CT显像,其低全身有效剂量和低于2-[18F]FDG的多数器官本底有利于病灶检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study, a novel aluminium-[18F]fluoride (Al18F)-labelled 1,4,7‑triazacyclononane-N,N',N″-triacetic acid (NOTA)-conjugated fibroblast activation protein inhibitor (FAPI) probe, named Al18F-NOTA-FAPI, was developed for fibroblast activation protein (FAP)-targeted tumour imaging; it could deliver hundreds of millicuries of radioactivity using automated synthesis. The tumour detection efficacy of Al18F-NOTA-FAPI was further validated in both preclinical and clinical translational studies. METHODS: The radiolabelling procedure of Al18F-NOTA-FAPI was optimized. Cell uptake and competitive binding assays were completed with the U87MG and A549 cell lines to evaluate the affinity and specificity of the Al18F-NOTA-FAPI probe. The biodistribution, pharmacokinetics, radiation dosimetry and tumour imaging efficacy of the Al18F-NOTA-FAPI probe were researched in healthy Kunming (KM) and/or U87MG model mice. After the approval of the ethical committee, the Al18F-NOTA-FAPI probe was translated into the clinic for PET/CT imaging of the first 10 cancer patients. RESULTS: The radiolabelling yield of Al18F-NOTA-FAPI was 33.8 ± 3.2% using manual synthesis (n = 10), with a radiochemical purity over 99% and the specific activity of 9.3-55.5 MBq/nmol. The whole body effective dose of Al18F-NOTA-FAPI was estimated to be 1.24E - 02 mSv/MBq, which was lower than several other FAPI probes (68Ga-FAPI-04, 68Ga-FAPI-46 and 68Ga-FAPI-74). In U87MG tumour-bearing mice, Al18F-NOTA-FAPI showed good tumour detection efficacy based on the results of micro PET/CT imaging and biodistribution studies. In an organ biodistribution study of patients, Al18F-NOTA-FAPI showed a lower SUVmean than 2-[18F]-fluoro-2-deoxy-D-glucose (2-[18F]FDG) in most organs, especially in the liver (1.1 ± 0.2 vs. 2.0 ± 0.9), brain (0.1 ± 0.0 vs. 5.9 ± 1.3), and bone marrow (0.9 ± 0.1 vs. 1.7 ± 0.4). Meanwhile, Al18F-NOTA-FAPI did not show extensive bone uptake, and was able to detect more lesions than 2-[18F]FDG in the PET/CT imaging of several patients. CONCLUSION: The Al18F-NOTA-FAPI probe was successfully fabricated and applied in fibroblast activation protein-targeted tumour PET/CT imaging, which showed excellent imaging quality and tumour detection efficacy in U87MG tumour-bearing mice as well as in cancer patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000038080. Registered 09 September 2020. http://www.chictr.org.cn/showproj.aspx?proj=61192.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang S, Zhou X, Xu X, et al. Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021. PMID: 34165601. doi:10.1007/s00259-021-05470-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。